Hesperidin RCT in MS
ConditionMultiple Sclerosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSwansea University
About this trial
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.
Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Eligibility criteria
Qualifiers
Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Disqualifiers
Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
Trial design
Treatments tested in this trial
- Hesperidin
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Swansea University
Lead sponsor
BioActor B.V.
Collaborator
Source ClinicalTrials.gov